

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Gaush Meditech Ltd**

**高视医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2407)**

## **VOLUNTARY ANNOUNCEMENT COOPERATION WITH HAAG-STREIT ON DISTRIBUTION OF CERTAIN OPHTHALMIC MEDICAL DEVICES**

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that, previously, Gaush Medical Corporation (高視醫療科技集團有限公司), a wholly-owned subsidiary of the Company, entered into a distribution agreement (the “**Agreement**”) with HAAG-STREIT AG (“**HAAG-STREIT**”), a company established in Switzerland, regarding the distribution of certain diagnostic medical devices (the “**Medical Devices**”) including but not limited to, full-line series No. 900 slit lamp microscopes, LENSTAR 900 optical biometer and Octopus 900/600 perimeter. Certain subsidiaries of the Company were officially granted with exclusive rights to market, sell and distribute the Medical Devices of HAAG-STREIT in Chinese mainland for an initial term commenced from March 7, 2023 and until December 31, 2025, the extension of which is subject to further negotiation between Gaush Medical Corporation and HAAG-STREIT.

The Group will work closely with HAAG-STREIT to continuously make advanced ophthalmic medical devices for diagnostics and examination, to actively promote the innovation and development of ophthalmic medical devices in China, and to jointly contribute to the development of ophthalmic medical industry of China.

## **ABOUT THE MEDICAL DEVICES**

The full-line series No. 900 slit lamp microscopes are well-known in the industry as the most high-end luxury slit lamp series. Their perfect optical properties, powerful functions and easy operation have become the standard for high-grade ophthalmic slit-lamp microscopes and are recognized and favored by ophthalmic experts.

The LENSTAR 900 optical biometer provides highly accurate laser optical measurements from the cornea to the retina, and it provides the best refractive planning platform for cataract surgery.

Octopus 900/600 perimeter inherited the essence of Goldmann's perimeter, which was developed by professor Goldmann and HAAG-STREIT in 1950s. With more than a half century of history, Octopus 900/600 perimeter has become the gold standard for computer perimetry.

## **ABOUT HAAG-STREIT**

HAAG-STREIT is a company from Berne, Switzerland with a history of over 165 years. HAAG-STREIT is famous in the ophthalmic industry for its exquisite and excellent optical designs. It is primarily engaged in providing ophthalmologist with ingenuity and eternal quality optical devices for precision examination and diagnostics.

To the best knowledge of the Directors, HAAG-STREIT is not a connected person of the Company within the meaning of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as of the date of this announcement.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board

**Gaush Meditech Ltd**

**Mr. Gao Tieta**

*Chairman and Executive Director*

Hong Kong, March 24, 2023

*As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Zhang Jianjun, Mr. Liu Xinwei and Mr. Zhao Xinli as executive Directors, Dr. David Guowei Wang and Mr. Shi Long as non-executive Directors, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.*